| Autor: |
Roberta Foresti, Vivien E. Prise, Roberto Motterlini, James Clark, Chryso Kanthou, Amel F. Khelifi, Gillian M. Tozer |
| Rok vydání: |
2002 |
| Předmět: |
|
| Zdroj: |
Heme Oxygenase in Biology and Medicine ISBN: 9781461352198 |
| DOI: |
10.1007/978-1-4615-0741-3_26 |
| Popis: |
In recent years there has been increasing interest in exploiting the tumour vasculature as a target for cancer therapy. It is now well established that the growth and expansion of malignant tumours is critically dependent on the establishment of a vascular network assuring nutritive blood flow (Folkman, 1990). However, a number of solid tumours are now known to be characterised by an inadequate vascularisation consisting of a temporally and spatially heterogeneous blood supply (Vaupel et al., 1989). Vascular targeting has received increasing interest in the past few years. This strategy aims at targeting the established tumour vasculature causing direct shut down in tumour blood flow, leading to secondary tumour cell death (Chaplin et al., 1998). Combretastatin A4-phosphate (CA-4-P) is the lead compound of a number of tubulin binding agents which cause selective vascular shut down in experimental tumours. It entered clinical trial in 1998. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
